Skip to content
FIRALIS S.A. logo — Innovative biomarker solutions for improved diagnostics, enh...

FIRALIS S.A.

Innovative biomarker solutions for improved diagnostics, enhancing patient outcomes and optimizing healthcare costs.

Founded 2008 France France 28 employees Series B Total: $1.93M Biotechnology, Health Care +1

General Information

Company Name FIRALIS S.A.
Founded Year 2008
Location France France
Employees 28
Industries Biotechnology, Health Care, Industrial
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with FIRALIS S.A.. To contact FIRALIS S.A., visit firalis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does FIRALIS S.A. compare?

A PDF of FIRALIS S.A. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting FIRALIS S.A. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About FIRALIS S.A.

FIRALIS S.A. is a leading biotechnology company based in Basel, Switzerland, specializing in innovative biomarker solutions for enhanced diagnostics, improved patient outcomes, and optimized healthcare costs. Since its establishment in 2008, the company has been at the forefront of biomarker (BM) discovery, development, and qualification, with a focus on cardiovascular, inflammatory, autoimmune, and neurology-related biomarkers. The company's offerings encompass a range of products and services, including RUO Kits (Research-Use-Only) and IVD Tools (In Vitro Diagnostic) that are based on clinically qualified biomarkers. Additionally, Firalis provides biomarker-related CRO services, including proteomics, genomics/transcriptomics, flow cytometry, assay development, biobanking, sample repository services, and data analysis tailored to the specific requirements of laboratories, biotechs, and the pharmaceutical industry. The latest investment of €1.48M in Series B funding received on 04 July 2013 from Auriga Partners and Financiere De l'Echiquier serves as a testament to the confidence that notable investors have in Firalis' innovative approach and its potential to advance the field of biomarker-based diagnostics and personalized medicine. For further insights into their pioneering work, interested parties can visit their website for additional information.

Business keywords: biomarker development, diagnostic tools, biomarker R&D, drug safety, personalized medicine, biomarker-related CRO services, proteomics, genomics, transcriptomics, flow cytometry, assay development, biobanking, regulatory qualification, precision medicine, Alzheimer's

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €1.48M 2
Auriga Partners, Financiere De l'Echiquier
04 Jul 2013
Seed Round €450.00K 1
SODIV ALSACE
30 Jun 2010

FIRALIS S.A. Alternatives & Competitors

View All Alternatives
FIRALIS S.A. vs
RogCon, Inc.
RogCon, Inc. United States

The SCN2A Company

7 employees
Biotechnology, Health Care
FIRALIS S.A. vs

Company specializing in the genomics of cancer and genetic diseases

Post-IPO Equity
50 employees
Biotechnology, Health Care
FIRALIS S.A. vs
Biognosys
Biognosys Switzerland

Transforming life sciences with cutting-edge proteomics technology and solutions

Series G
90 employees
Biotechnology, Health Care

FAQ About FIRALIS S.A.

Innovative biomarker solutions for improved diagnostics, enhancing patient outcomes and optimizing healthcare costs.
FIRALIS S.A. was founded in 2008.
FIRALIS S.A. is headquartered in France.
FIRALIS S.A. operates in Biotechnology, Health Care and Industrial. Its work centres on biomarker development, diagnostic tools, biomarker R&D and drug safety.
FIRALIS S.A. has approximately 28 employees.
FIRALIS S.A. has completed 2 funding rounds, raising a total of $1.93M. The latest funding stage is Series B.
Top alternatives and competitors to FIRALIS S.A. include RogCon, Inc., IntegraGen, Biognosys, AATec Medical, PrecisionLife. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FIRALIS S.A. and RogCon, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for FIRALIS S.A., https://bouncewatch.com/company/firalis, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout